Inovio Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Inovio Pharmaceuticals, Inc.
US demands for 30,000 subject studies and harmonized protocols mean a robust result could arrive soon – but recruitment could still be a challenge.
Denmark-based UNION therapeutics has bought LEO Pharma’s PDE4 inhibitor compound series for use in developing treatments for psoriasis and atopic dermatitis.
Relay raises $400m to kick off July’s second big week of US initial public offerings. Also, Ocumension and Immunotech launch Hong Kong IPOs, Amgen invests $421m in BeiGene’s $2.08bn offering, Cytokinetics gets up to $400m in deal and investment funding, and Imvax closes $111m series C round.
The UK biotech will have no problems funding a Phase III program for its nebulized first-in-class COPD therapy ensifentrine as investors old and new flocked to buy into the stock.
- Medical Devices
- Gene Therapy, Cell Therapy
- Large Molecule
Drug Discovery Tools
- Other Names / Subsidiaries
- Bioject Medical Technologies
- Inovio Biomedical
- VGX Pharmaceuticals